Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other financing activities (2016 - 2025)

Ironwood Pharmaceuticals' Other financing activities history spans 13 years, with the latest figure at $121000.0 for Q4 2025.

  • For Q4 2025, Other financing activities rose 34.44% year-over-year to $121000.0; the TTM value through Dec 2025 reached $216000.0, down 90.38%, while the annual FY2025 figure was $216000.0, 90.38% down from the prior year.
  • Other financing activities for Q4 2025 was $121000.0 at Ironwood Pharmaceuticals, up from $1000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $10.1 million in Q1 2024 and bottomed at -$8.0 million in Q3 2024.
  • The 5-year median for Other financing activities is $1.1 million (2022), against an average of $1.9 million.
  • The largest annual shift saw Other financing activities surged 887.76% in 2021 before it tumbled 61838.46% in 2024.
  • A 5-year view of Other financing activities shows it stood at $5.6 million in 2021, then fell by 8.63% to $5.2 million in 2022, then crashed by 88.54% to $591000.0 in 2023, then plummeted by 84.77% to $90000.0 in 2024, then surged by 34.44% to $121000.0 in 2025.
  • Per Business Quant, the three most recent readings for IRWD's Other financing activities are $121000.0 (Q4 2025), $1000.0 (Q3 2025), and $88000.0 (Q2 2025).